Serum Neutrophil Gelatinase-Associated Lipocalin and Cystatin C are early Biomarkers of Contrast-Induced Nephropathy After Coronary Angiography in Patients With Chronic Kidney Disease
Restricted accessResearch articleFirst published online May, 2014
Serum Neutrophil Gelatinase-Associated Lipocalin and Cystatin C are early Biomarkers of Contrast-Induced Nephropathy After Coronary Angiography in Patients With Chronic Kidney Disease
We had previously reported on serum neutrophil gelatinase-associated lipocalin (NGAL) as an earlier biomarker of contrast-induced nephropathy (CIN) than serum creatinine (SCr) in 100 patients with chronic kidney disease undergoing coronary angiography.1 We then compared serum NGAL to serum cystatin C (CysC) in the same group of patients. The SCr, estimated glomerular filtration rate, serum NGAL, and serum CysC were measured at baseline and various time points as appropriate postprocedure. The frequency of CIN was 11% (n = 11). Serum NGAL increased ≥25% from baseline at 24 hours in 7 patients with CIN (P = .04). Serum CysC increased ≥25% from baseline at 24 hours in 4 patients with CIN (P = .008). Changes in serum NGAL and serum CysC from baseline at 24 hours (▵ values) could diagnose CIN 24 hours earlier than SCr with serum NGAL showing a superior performance.
AlharazySMKongNSaidinR. Neutrophil gelatinase-associated lipocalin as an early marker of contrast-induced nephropathy after coronary angiography [published online January 31, 2013]. Angiology. 2013.
2.
NashKHafeezAHouS. Hospital-acquired renal insufficiency. Am J Kidney Dis. 2002;39(5):930–936.
3.
RosnerMHOkusaMD. Acute kidney injury associated with cardiac surgery. Clin J Am Soc Nephrol. 2006;1(1):19–32.
4.
MurrayPTLe GallJRDos Reis MirandaDPinskyMRTettaC. Physiological endpoints (efficacy) for acute renal failure. Curr Opin Crit Care. 2002;8(6):519–525.
5.
Bachorzewska-GajewskaHMalyszkoJSitniewskaE. Could neutrophil gelatinase-associated lipocalin and cystatin C predict the development of contrast induced nephropathy after percutaneous coronary interventions in patients with stable angina and normal serum creatinine values?Kidney Blood Press Res. 2007;30(6):408–415.
6.
RickliHBenouKAmmannP. Time course of serial cystatin C levels in comparison with serum creatinine after application of radiocontrast media. Clin Nephol. 2004;61(2):98–102.
7.
MoriKLeeHTRapoportD. Endocytic delivery of lipocalin–siderophore–iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest. 2005;115(3):610–621.
8.
MishaJMaQKellyC. Kidney NGAL is a novel early marker of acute renal injury following transplantation. Pediatr Nephrol. 2006;21(6):856–863.
9.
Herget-RosenthalSPoppenDHusingJ. Prognostic value of tubular proteinuria and enzymuria in non oliguric acute tubular necrosis. Clin Chem. 2004;50(3):552–558.
10.
HanWKBaillyVAbichandaniRThadhaniRBonventreJV. Kidney injury molecule-1 (KIM-1): a novel biomarker for human real proximal tubule injury. Kidney Int. 2002;62(1):237–244.
11.
Herget-RosenthalSMarggrafGHusingJ. Early detection of acute renal failure by serum cystatin C. Kidney Int. 2004;66(3):1115–1122.
12.
LeveyASBoschJPLewisJBGreeneTRogersNRothD. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med1999;130(6):461–470.
13.
RihalCSTextorSCGrillDE. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002;105(19):2259–2264.
14.
ManjunathGTighiouartHCoreshJ. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int. 2003;63(3):1121–1129.
15.
Raposeiras-RoubínSAguiar-SoutoPBarreiro-PardalC. Grace risk score predicts contrast-induced nephropathy in patients with acute coronary syndrome and normal renal function. Angiology. 2013;64(1):31–39.
16.
FuNLiXYangS. Risk score for the prediction of contrast-induced nephropathy in elderly patients undergoing percutaneous coronary intervention. Angiology. 2013;64(3):188–194.
17.
BirckRKrzossokSMarkowetzFSchnullePvan der WoudeFJBraunC. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet. 2003;362(9384):598–603.
18.
LiuRNairDIxJMooreDHBentS.N-acetylcysteine for the prevention of contrast-induced nephropathy. A systematic review and meta-analysis. J Gen Intern Med. 2005;20(2):193–200.
19.
NallamothuBKShojaniaKGSaintS. Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis. Am J Med. 2004;117(12):938–947.
20.
O'SullivanSHealyDAMoloneyMCGracePAWalshSR. The role of N acetylcysteine in the prevention of contrast-induced nephropathy in patients undergoing peripheral angiography: a structured review and meta-analysis [published online November 27, 2012]. Angiology. 2012.
21.
SadatUWalshSRNordenAGGillardJHBoyleJR. Does oral N-acetylcysteine reduce contrast-induced renal injury in patients with peripheral arterial disease undergoing peripheral angiography? A randomized-controlled study. Angiology. 2011;62(3):225–230.
22.
JoSH. N-acetylcysteine for prevention of contrast-induced nephropathy: a narrative review. Korean Circ J. 2011;41(12):695–702.
23.
MuellerCBuerkleGBuettnerHJ. Prevention of contrast media associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med. 2002;162(3):329–336.
24.
SolomonRWernerCMannDD’EliaJSilvaP. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med. 1994;331(21):1416–1420.
25.
MertenGJBurgessWPGrayLV. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA. 2004;291(19):2328–2334.
26.
StevensMAMcCulloughPATobinKJ. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study: prevention of radiocontrast induced nephropathy clinical evaluation. J Am Coll Cardiol. 1999;33(2):403–411.
27.
ShemiraniHPourrmoghaddasM. A randomized trial of saline hydration to prevent contrast-induced nephropathy in patients on regular captopril or furosemide therapy undergoing percutaneous coronary intervention. Saudi J Kidney Dis Transpl. 2012;23(2):280–285.
28.
BagshawSMCulletonBF. Contrast-induced nephropathy: epidemiology and prevention. Minerva Cardioangiol. 2006;54(1):109–129.
29.
TalatiSKirtaneAJHassaninA. Direct infusion of fenoldopam into the renal arteries to protect against contrast-induced nephropathy in patients at increased risk. Clin Exp Pharmacol Physiol. 2012;39(6):506–529.
30.
OguzhanNCilanHSipahiogluM. The lack of benefit of a combination of an angiotensin receptor blocker and calcium channel blocker on contrast-induced nephropathy in patients with chronic kidney disease [published online February 18, 2013]. Ren Fail. 2013.
31.
TosoAMaioliMLeonciniM. Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease. Am J Cardiol. 2010;105(3):288–292.
32.
OzhanHErdenIOrduS. Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography. Angiology. 2010;61(7):711–714.
33.
Li ZhouLChenH. Prevention of contrast-induced nephropathy with ascorbic acid. Intern Med. 2012;51(6):531–535.
34.
Diaz-SandovalLJKosowskyBDLosordoDW. Acetylcysteine to prevent angiography-related renal tissue injury (The APART Trial). Am J Cardiol. 2002;89(3):356–358.
35.
CroninRE. Renal failure following radiologic procedures. Am J Med Sci. 1989;298(5):342–356.
36.
MurphySWBarrettBJParfreyPS. Contrast nephropathy. J. Am Soc Nephrol. 2000;11(1):177–182.
37.
DevarajanP. Emerging biomarkers of acute kidney injury. Contrib Nephrol. 2007;156:203–212.
38.
Bachorzewska-GajewskaHMalyszkoJSitniewskaE. NGAL (neutrophil gelatinase-associated lipocalin) and cystatin C: are they good predictors of contrast nephropathy after percutaneous coronary interventions in patients with stable angina and normal serum creatinine?Int J Cardiol. 2008;127(2):290–291.
39.
ShakerOEl-ShehabyAEl-KhatibM. Early diagnostic markers for contrast nephropathy in patients undergoing coronary angiography. Angiology. 2010:61(8):731–736.
40.
LiuXLWangZJYangQ. Plasma neutrophil-gelatinase-associated lipocalin and cystatin C could early diagnose contrast-induced acute kidney injury in patients with renal insufficiency undergoing an elective percutaneous coronary intervention. Chin Med J. 2012;125(6):1051–1056.
41.
BriguoriCViscontiGRiveraNV. Cystatin C and contrast-induced acute kidney injury. Circulation. 2010;121(19):2117–2122.
42.
IshibashiYYamauchiMMushaHMikamiTKawasakiKMiyakeF. Impact of contrast-induced nephropathy and cardiovascular events by serum cystatin C in renal insufficiency patients undergoing cardiac catheterization. Angiology. 2010;61(8):724–730.
43.
LingWZhaohuiNBenH. Urinary IL-18 and NGAL as early predictive biomarkers in contrast-induced nephropathy after coronary angiography. Nephron Clin Pract. 2008;108(3):c176–c181.
